Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake.
Receptors for the Fc fragment of immunoglobulin G (FcγRs) are important molecules not only to mediate and control the effectors' functions of IgG antibodies, but they also control the autoimmunity-tolerance balance in the periphery. In humans, three different types of FcγRs, belonging to the Ig gene superfamily, have been identified; FcγRI (cluster of differentiation (CD64), FcγRII (CD32) and FcγRIII (CD16). A wide range of inflammatory and autoimmune diseases, such as vasculitis, glomerulonephritis, and autoimmune hemolytic anemia, seems to be mediated, in part, by FcγRs. Recent findings supposed that, under certain conditions, FcγRs are involved in the penetration of antibodies into cells and FcγRs constitute one of the main effector mechanisms through which autoantibodies exert their action. In this review, we concentrate on the role of human FcγRs in autoantibodies penetration and summarize the current knowledge on the structure, ligand binding capacity and their role in autoimmunity and pathogenic effect of autoantibodies.
Lisi
Sabrina
S
Department of Human Anatomy and Histology, Section of Cell Biology, University of Bari Medical School, Bari, Italy.
Sisto
Margherita
M
Lofrumento
Dario Domenico
DD
D'Amore
Simona
S
D'Amore
Massimo
M
D000744:Anemia, Hemolytic, Autoimmune / Q000473:pathology; D001323:Autoantibodies / Q000276:immunology* / Q000378:metabolism*; D005921:Glomerulonephritis / Q000473:pathology; D006801:Humans; D017452:Receptors, IgG / Q000276:immunology* / Q000378:metabolism*; D014657:Vasculitis / Q000473:pathology
D001323:Autoantibodies; D017452:Receptors, IgG
Isr Med Assoc J. 2008 Jan;10(1):13-9
18300564
Dig Dis Sci. 2005 Jan;50(1):181-187
27837389
J Gen Virol. 2001 May;82(Pt 5):1137-1145
11297688
J Clin Invest. 2002 Nov;110(10):1549-57
12438452
Arthritis Res Ther. 2007;9(3):R51
17521421
J Autoimmun. 1998 Oct;11(5):547-56
9802942
Experientia. 1979 Jun 15;35(6):763-5
467580
Autoimmun Rev. 2007 Jun;6(6):325-33
17537376
Curr Opin Immunol. 1996 Apr;8(2):199-205
8725943
Cell Biol Toxicol. 1998 Aug;14(4):261-6
9733281
Muscle Nerve. 1999 Aug;22(8):1030-7
10417783
Rheumatol Int. 2008 Jul;28(9):943-8
18264709
Adv Immunol. 1994;57:1-127
7872156
J Neurosci. 2000 May 15;20(10):3552-62
10804196
Clin Exp Immunol. 1999 Mar;115(3):554-60
10193433
No To Shinkei. 1990 Oct;42(10):945-50
1705127
J Immunol. 1979 May;122(5):1855-62
376727
J Am Soc Nephrol. 1996 Jun;7(6):946-54
8793805
Expert Opin Ther Targets. 2005 Feb;9(1):169-90
15757489
Nature. 2000 Jul 20;406(6793):267-73
10917521
J Immunol. 1992 Mar 1;148(5):1471-8
1311348
Environ Health Perspect. 1999 Oct;107 Suppl 5:767-75
10502543
FASEB J. 2004 Jan;18(1):182-4
14630707
Int Immunol. 1999 Apr;11(4):605-15
10323214
J Autoimmun. 1998 Oct;11(5):557-61
9802943
Cell. 1994 Feb 11;76(3):519-29
8313472
Nature. 1979 Jun 21;279(5715):679-85
221835
Circ Res. 1989 Feb;64(2):179-92
2536302
J Autoimmun. 2000 Aug;15(1):15-20
10936024
J Autoimmun. 1998 Oct;11(5):523-33
9802939
Rheumatology (Oxford). 2005 Jun;44(6):729-34
15757966
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11076-81
15258288
Clin Exp Rheumatol. 2008 Jan-Feb;26(1):89-95
18328152
N Engl J Med. 2003 Oct 16;349(16):1526-33
14561795
Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):377-92
14561184
Scand J Rheumatol. 1990;19(2):123-35
1692420
J Autoimmun. 1998 Oct;11(5):535-8
9802940
Clin Rev Allergy Immunol. 2002 Dec;23(3):279-99
12402413
J Immunol. 2000 Jun 1;164(11):6020-6
10820286
J Invest Dermatol. 2002 Nov;119(5):1074-9
12445195
J Mol Biol. 2000 Jan 14;295(2):213-24
10623521
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12266-71
11050246
J Immunol. 2001 Mar 15;166(6):3882-9
11238632
J Exp Med. 1989 Aug 1;170(2):481-97
2526846
Nat Struct Biol. 1999 May;6(5):437-42
10331870
J Clin Immunol. 2005 Jan;25(1):1-18
15742153
J Oral Pathol Med. 2007 Oct;36(9):511-23
17850433